Pancreatic Cancer Research

ResearcherHirosaki UniversityActive in the last 2 years

Keinosuke Ishido

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0342-1199; OpenAlex author ID A5067928410. Sources: OpenAlex.

Their work

Papers
21 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 5 papers

Papers 21

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2026.106238↗
  3. Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Prop… Co-author DOI 10.1016/j.jss.2026.08.063↗
  4. MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer. Co-author DOI 10.1016/j.modpat.2025.100953↗
  5. Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy. First author DOI 10.1097/mpa.0000000000002706↗
  6. Noninvasive Computed Tomography-Based Deep Learning Model Predicts In Vitro Chemosensitivity Assay Results in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002270↗
  7. Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer: A propensity score matching analysis. First author DOI 10.3892/ol.2024.14369↗
  8. Dual epigenetic changes in diabetes mellitus-associated pancreatic ductal adenocarcinoma correlate with downregulation of E-cadherin and worsened prognosis. Co-author DOI 10.1002/cjp2.326↗
  9. Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemothera… Co-author DOI 10.3892/or.2023.8498↗
  10. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Re… Co-author DOI 10.1245/s10434-021-10920-3↗
  11. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12379↗
  12. Roles of the nervous system in pancreatic cancer. First author DOI 10.1002/ags3.12459↗
  13. Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer. First author DOI 10.1038/s41598-021-00727-3↗
  14. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching A… Co-author DOI 10.1097/mpa.0000000000001913↗
  15. Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. Co-author DOI 10.3892/ol.2021.12537↗
  16. [A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery]. First author PMID 32156995↗
  17. [A Case of Remnant Pancreatic Cancer after Conversion Surgery for Advanced Distal Bile Duct Cancer Treated with Chemotherapy]. Co-author PMID 30692392↗
  18. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. First author DOI 10.3892/mco.2017.1251↗
  19. [Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy]. Co-author PMID 24393952↗
  20. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.21880↗
  21. Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer. Co-author DOI 10.3892/ol.2011.412↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichi Hakamada · 20 shared papers, 2011–2026 · strength 3.15
  2. Hayato Nagase · 9 shared papers, 2019–2026 · strength 1.83
  3. Taiichi Wakiya · 10 shared papers, 2013–2026 · strength 1.59
  4. Yusuke Wakasa · 4 shared papers, 2018–2026 · strength 1.01
  5. Taishu Kanda · 6 shared papers, 2021–2024 · strength 0.98
  6. Satoru Tsuruta · 3 shared papers, 2026 · strength 0.93
  7. Tadashi Yoshizawa · 5 shared papers, 2021–2026 · strength 0.87
  8. Hiroshi Kijima · 5 shared papers, 2011–2026 · strength 0.72
  9. Shintaro Goto · 3 shared papers, 2021–2026 · strength 0.58
  10. Yutaro Hara · 3 shared papers, 2022–2026 · strength 0.57
  11. Kenta Ogasawara · 2 shared papers, 2023–2026 · strength 0.43
  12. Keisuke Yamazaki · 2 shared papers, 2023–2026 · strength 0.41
  13. Yoshiki Nishiyama · 1 shared paper, 2026 · strength 0.26
  14. Daisuke Kudo · 4 shared papers, 2011–2018 · strength 0.23
  15. Eri Yoshida · 1 shared paper, 2024 · strength 0.20
  16. Hideki Motobayashi · 1 shared paper, 2026 · strength 0.18
  17. Joe Matsumoto · 1 shared paper, 2026 · strength 0.18
  18. Yosuke Inoue · 1 shared paper, 2026 · strength 0.18
  19. Masaaki Murakawa · 1 shared paper, 2026 · strength 0.18
  20. Sohei Satoi · 1 shared paper, 2026 · strength 0.18
  21. Masamichi Hayashi · 1 shared paper, 2026 · strength 0.18
  22. Aoi Hayasaki · 1 shared paper, 2026 · strength 0.18
  23. Takayoshi Nakajima · 1 shared paper, 2026 · strength 0.18
  24. Yoshitaro Shindo · 1 shared paper, 2026 · strength 0.18
  25. Masafumi Imamura · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.